Recently Introduced Products

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Indication</th>
<th>Potential Impact</th>
<th>Expected Avg. Annual Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xeomin</td>
<td>For the symptomatic management of blepharospasm, cervical dystonia (spasmodic torticollis) and post-stroke spasticity of the upper limbs in adults</td>
<td>$$</td>
<td>$3,300</td>
</tr>
<tr>
<td>Apri</td>
<td>For conception control</td>
<td>$</td>
<td>$119.60</td>
</tr>
</tbody>
</table>

$: Est. drug plan expenditure increase of <1%*  $$: Est. drug plan expenditure increase of 1-5%*  $$$: Est. drug plan expenditure increase of >5%*

Nplate® - Advancement in the treatment of chronic Idiopathic Thrombocytopenic Purpura

Idiopathic Thrombocytopenic Purpura (ITP) is an autoimmune disease in which blood platelets are destroyed by the body’s immune system at an increased rate, for no known reason (idiopathic). This condition results in low blood platelet levels and is often without symptoms. Since platelets are necessary for the formation of blood clots, a very low platelet count may lead to bruising (purpura) or more severe bleeding.1,2

ITP is a very rare disorder with approximately 50-100 new cases per million each year, half of which are in children. Over 70% of childhood cases result in remission within 6 months, regardless of treatment. On the other hand, ITP in adulthood is usually chronic. The probability of long-lasting remission is only 20 to 40%, hence the need for effective therapies.1,2

The goal of chronic ITP treatment is to maintain a normal platelet count. Initial therapy includes systemic corticosteroids, such as prednisone. Second and third-line treatments include removal of the spleen (splenectomy) and drugs used outside their approved indications, such as Danazol and azathioprine. In emergency situations where there is severe bleeding, administration of high-dose intravenous immunoglobulins (IVIg) or a platelet transfusion may be required.1,2

Nplate (romiplostim) is a new maintenance therapy indicated to increase platelet levels in adults with chronic ITP who have had inadequate response to traditional therapies. Nplate activates and stimulates the production of blood platelets. It is administered by subcutaneous injection once weekly, with the dose based on the patient’s weight and platelet count. Nplate may be used alone or in combination with other ITP therapies, possibly reducing the dosage or allowing complete discontinuation of previous ITP therapy.1,3

The annual cost of treatment with Nplate® is approximately $45,890 to $183,560, depending on the required dose. Nplate will be excluded from all ClaimSecure drug plans and Managed Formularies for the following reasons: ITP is a rare disease, alternate treatments are available and the cost of treatment with Nplate can become cost prohibitive.

If you require additional information about Nplate®, please contact Shellina Sevany, Manager, Clinical Services Department, at (905) 949-3025 or 1-888-479-7587 ext.3025.

Recommendation: Exclude

ClaimSecure reserves the right to amend in part or in its entirely stated special authorization clinical guidelines

References:


© 2008 ClaimSecure Inc.